MedX Health Appoints Dr. Symon Cotton as Strategic Advisor to Advance AI and Product Development in Teledermatology

MedX Health Corp. (TSXV: MDX), a global leader in teledermatology and non-invasive skin analysis, has announced the appointment of Dr. Symon D. Cotton as a Strategic Advisor on AI and Product Development. Based in Mississauga, Ontario, the company said the move strengthens its commitment to advancing AI-powered diagnostics and innovation in skin health. Dr. Cotton, a distinguished figure in medical technology, brings decades of experience at the intersection of engineering, biology, and computation. Currently serving as Head of Life Sciences at a prominent technology organization, he has led multiple successful ventures in medical device development and digital health platforms. He is one of the original scientific architects behind Spectrophotometric Intracutaneous Analysis (SIAscopy®), a breakthrough technology co-developed with Dr. Paul Matts. Their pioneering work enabled the first non-invasive, simultaneous measurement of melanin, hemoglobin, and collagen in the skin—key biomarkers for early skin cancer detection. This foundational science has become central to MedX’s DermSecure® platform, which powers its global teledermatology services. Dr. Cotton’s expertise extends into AI-driven analytics for medical imaging, a domain that aligns closely with MedX’s strategic goals. His deep knowledge in computational biology, device design, and translational medicine will support the company’s efforts to enhance its AI models using SIAscopy’s extensive, high-resolution imaging data. This advancement aims to improve diagnostic accuracy, scalability, and clinical outcomes. “I am proud to have helped shape the early development of SIAscopy and am excited to return to this field at such a transformative time,” said Dr. Cotton. “With AI rapidly reshaping healthcare, I look forward to supporting MedX in leveraging its unique imaging database and DermSecure® platform to drive earlier, more reliable skin cancer detection across the world.” John Gevisser, CEO of MedX Health, emphasized the significance of Dr. Cotton’s role: “Dr. Cotton’s contributions were foundational to the development of SIAscopy, the technology that powers our global teledermatology platform. His leadership in medical device innovation and AI strategy will be instrumental as we continue to push the boundaries of skin optics and machine learning—ensuring our solutions remain both scientifically rigorous and commercially viable.” MedX Health Corp. specializes in non-invasive skin assessment and digital dermatology solutions. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, allows for pain-free, high-accuracy imaging of skin lesions, enabling rapid evaluation by dermatologists. The platform is approved by Health Canada, the U.S. FDA, the Therapeutic Goods Administration (Australia), and CE marking, and is currently deployed in 38 countries, including the U.S., Canada, the UK, the EU, Australia, New Zealand, and Turkey. Through its secure, cloud-based system, MedX empowers healthcare providers to efficiently assess suspicious moles and skin conditions, improving access to dermatological care and supporting early diagnosis. For more information, visit https://www.medxhealth.com. This media release contains forward-looking statements that reflect the company’s current expectations regarding future events. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.